VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 22, 2008) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") is pleased to announce that Australian Patent Number 2002322916 has been issued by the Australia Patent Office. The patent provides protection for the composition and production methods for ALDA's T36(R) formulation until August 20, 2022.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection control therapeutics derived from its patented T36(R) technology. The company trades on the TSX Venture Exchange under the symbol APH.